Asthma–COPD overlap

**KEY POINTS**

Many adults have features of both asthma and chronic obstructive pulmonary disease (COPD). This is described as asthma–COPD overlap.

Asthma–COPD overlap is not a single disease, but is likely to have many underlying causes. It can develop in smokers, ex-smokers or non-smokers, particularly at older ages.

Patients with asthma–COPD overlap are at higher risk than patients with either condition alone, with more symptoms, more flare-ups, greater need for health care utilisation, and higher mortality.

Asthma–COPD overlap should be considered in adults when they have a history of asthma or have asthma-like symptoms, and spirometry before and after bronchodilator shows expiratory airflow limitation that is not completely reversible.

Specialist referral may be needed if there is doubt about the diagnosis, and to optimise treatment.

Treatment of patients with asthma–COPD overlap involves long-term inhaled corticosteroid (ICS) treatment to reduce the risk of asthma flare-ups. Most patients should also have a trial of a long-acting beta$_2$ agonist (LABA) and/or long-acting muscarinic antagonist (LAMA).

The use of LABAs or LAMAs without concomitant ICS should be avoided in patients with any features of asthma, or a history of asthma, because this increases the risk of hospitalisation and death.

Management also includes treatment of comorbid conditions, smoking cessation, adequate physical activity, pulmonary rehabilitation, regular vaccinations, self-management education including an up-to-date written action plan, and regular follow-up.

Asthma and COPD are heterogeneous conditions, each with several different underlying causes. The definitions of asthma and COPD are not mutually exclusive, and a significant proportion of adults with obstructive respiratory disease have clinical features of both conditions.

Distinguishing between typical asthma (e.g. childhood-onset allergic asthma) and typical COPD (e.g. emphysema in a heavy smoker) is straightforward. However, it can be difficult to distinguish COPD from asthma in adults who have features of both conditions. These people are described as having asthma–COPD overlap. Asthma–COPD overlap is now recognised as an important clinical problem.

Asthma–COPD overlap is not a single, well-defined disease entity, but includes a range of airway disease phenotypes with different causal mechanisms (Figure 1). It can be considered as positioned within a spectrum of chronic obstructive respiratory disease.
In practice, asthma–COPD overlap is identified in clinical practice by the features that it shares with both asthma and COPD. Research show that people with asthma–COPD overlap may have airway eosinophilia, neutrophilia, or a mixed pattern of airway inflammation, and may have systemic inflammation.

People with asthma–COPD overlap often have poor disease outcomes, including:

- high need for health care services
- worse quality of life, more wheezing, dyspnoea, cough and sputum production, and more frequent and severe respiratory exacerbations and hospitalisations, than people with COPD or asthma alone
- worse lung function demonstrated by spirometry than those with COPD alone, despite lower average exposure to tobacco smoke.

It is important to identify people with asthma–COPD overlap, because they are at higher risk than patients with asthma or COPD alone, and because they should be treated differently from people with COPD or asthma alone.
Asthma management guidelines and COPD management guidelines make opposing safety recommendations: in asthma, long-acting bronchodilators should never be used without ICS, while in COPD, treatment should start with long-acting bronchodilators without ICS.

There is very limited evidence to guide pharmacological treatment for people with asthma–COPD overlap, because these patients are excluded from most major pharmacologic studies of asthma or COPD treatment. The few available studies sampled from relevant populations have used different definitions of asthma–COPD overlap.

This information paper contains interim advice for health professionals, until firm guidelines can be developed from future research in this group of patients. Based on current understanding and evidence, a key safety precaution is to ensure that patients with any features of asthma receive regular ICS treatment.

Prevalence

Prevalence estimates for asthma–COPD overlap differ, depending on the definition used and whether the sample is population-based or hospital-based. Overall, approximately 20% of patients with obstructive airway disease have been diagnosed with both asthma and COPD: 12–55% of patients with a primary diagnosis of COPD and 13–61% of those with a primary diagnosis of asthma. If only spirometric criteria are used, the prevalence is much higher (approximately 50% of those aged over 50 years).

The coexistence of incompletely reversible expiratory airflow limitation (characteristic of COPD) and increased expiratory airflow variability (characteristic of asthma) is common among middle-aged adults with respiratory symptoms, especially people aged 65 years and over.

Diagnosis

Diagnosis is based on the probability of asthma or COPD, according to the presence of clinical features of either. If the diagnosis is unclear, consider referral to a respiratory physician.

History, clinical findings and spirometry

Based on history, physical examination and other investigations, identify features typical of asthma and typical of COPD (Figure 2).

Typical features of history include chronic or recurrent cough, sputum production, dyspnoea, wheezing, recurring acute lower respiratory tract infections, exposure to tobacco smoke or other airborne pollutants, a previous diagnosis of asthma or COPD, and the use of inhaled respiratory medicines. Lung auscultation can be normal or there may be wheeze.

If several features of both are present and neither is strongly favoured, manage according to recommendations for asthma–COPD overlap.

Spirometry

Perform spirometry before and after bronchodilator. If spirometry demonstrates expiratory airflow limitation that is not completely reversible (Table 1), consider the possibility of COPD (if risk factors such as smoking), or asthma–COPD overlap (with or without a history of smoking, if there are also any features of asthma).

Other investigations

Other investigations may be necessary to assess respiratory and other comorbidities. For more information, refer to COPD-X Concise Guide for Primary Care (available at copdx.org.au) and the Australian Asthma Handbook (asthmahandbook.org.au).

RISK FACTORS FOR DEVELOPING FIXED AIRFLOW LIMITATION IN ASTHMA

Among people with asthma, having one or more of these factors might increase the chance of developing fixed airflow limitation, but no factor is essential.

Modifiable factors

Smoking
Occupational asthma
Exposure to respiratory irritants such as industrial dusts and chemical fumes
Lack of ICS treatment for asthma

Demographics
Male sex
Ageing

History
Hospital admission for severe respiratory infection before age 2 years
Asthma diagnosis as a child
Long-term asthma
Adult-onset asthma
History of smoking (even low pack–years)
Chronic mucus hypersecretion

Findings on investigation
Low baseline FEV₁
Atopy

FEV₁: forced expiratory volume in 1 second; ICS: inhaled corticosteroid
Features that, when present, increase the probability of either asthma or COPD. None of these features is essential to make the diagnosis of asthma or COPD, with the exception of persistent airflow limitation for making the diagnosis of COPD. Absence of any of these features does not rule out asthma or COPD.

Adapted from GINA and GOLD (2017)
Figure 2. Features that, if present, favour asthma or COPD (continued from page 4)

* Expiratory airflow limitation: indicated by a reduced ratio of forced expiratory volume in one second (FEV₁) to forced vital capacity (FVC) on spirometry (FEV₁/FVC less than the lower limit of normal, i.e. less than the 5th percentile of normal population). Typical FEV₁/FVC values derived from population studies are > 0.75 in people aged 40–59 years and > 0.70 in people aged 60–80 years.

# Variable expiratory airflow limitation: variation beyond the range seen in healthy populations. It is indicated in adults by any of the following:

- a clinically important increase in FEV₁ (change in FEV₁ of at least 200 mL and 12% from baseline) 10–15 minutes after administration of bronchodilator
- a clinically important increase in lung function (at least 20% change in FEV₁) when measured repeatedly over time (e.g. spirometry on separate visits)
- a clinically important increase in lung function (at least 200 mL and 12% from baseline) after ≥ 4 weeks' treatment trial with an ICS
- clinically important variation in peak expiratory flow (diurnal variability of more than 10%, calculated over 1–2 weeks as the average of daily amplitude per cent mean)
- a clinically important reduction in lung function (decrease in FEV₁ of at least 200 mL and 12% from baseline on spirometry, or decrease in peak expiratory flow rate by at least 20%) after exercise (normal laboratory-based exercise challenge testing uses different criteria for exercise-induced bronchoconstriction)
- a clinically important reduction in lung function (15–20%, depending on the test) during a test for airway hyperresponsiveness (exercise challenge test or bronchial provocation test) measured by a respiratory function laboratory.

The greater the variations, or the more occasions excess variation is seen, the more confidently the diagnosis of variable expiratory airflow limitation consistent with asthma can be made.

† Persistent expiratory airflow limitation is indicated by reduced post-bronchodilator FEV₁/FVC

§ Lack of history of atopy does not preclude the presence of non-allergic asthma

‡ Chest X-ray may be normal in a patient with COPD

Table 1. Interpreting spirometry findings in adults

<table>
<thead>
<tr>
<th>Finding</th>
<th>Consistent with</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Asthma</td>
</tr>
<tr>
<td>Normal FEV₁/FVC before or after bronchodilator</td>
<td>Yes</td>
</tr>
<tr>
<td>Abnormal lung function (post-bronchodilator reduced FEV₁/FVC and FEV₁ &lt; lower limit of normal)</td>
<td>Yes*</td>
</tr>
<tr>
<td>Airflow limitation with greater bronchodilator reversibility than in healthy population (Post-bronchodilator FEV₁ increase ≥ 12% and 200 mL from baseline)</td>
<td>Yes§</td>
</tr>
<tr>
<td>Marked bronchodilator reversibility (FEV₁ increase ≥ 12% and 400 mL from baseline)</td>
<td>Yes</td>
</tr>
</tbody>
</table>

FEV₁/FVC: ratio of forced expiratory volume in one second (FEV₁) to forced vital capacity (FVC), either before or after bronchodilator

* Normal FEV₁/FVC is not consistent with COPD unless there is other evidence of chronic non-reversible expiratory airflow limitation.

# This finding is consistent with asthma that is poorly controlled or measured during a flare-up, or can be seen in some patients with longstanding asthma.

† The greater the variation, and the more times variation is seen, the more likely the diagnosis of asthma. However, some patients with longstanding asthma may develop persistent airflow limitation.

† Marked reversibility strongly favours asthma and is generally inconsistent with COPD, but does not rule out asthma–COPD overlap.

§ This finding may be seen in patients with asthma–COPD overlap, or occasionally in COPD, especially when FEV₁ is low.
Treatment

**KEY RECOMMENDATIONS**

If there are any features or history of asthma, prescribe regular, long-term ICS treatment to reduce the risk of asthma flare-ups.

Consider adding a long-acting bronchodilator (LAMA or LABA) if symptoms and/or flare-ups are not well controlled. Options include:

- an ICS plus a LABA (in a single inhaler, if possible)
- an ICS plus a LAMA
- the combination of an ICS, a LAMA and a LABA (with at least two of the agents in a single inhaler).

Provide all patients with as-needed short-acting beta agonist (SABA).

Reassess and repeat spirometry 6–8 weeks later.

Do not prescribe LABAs or LAMAs for patients with asthma–COPD overlap unless they are also using long-term ICS. Use combination inhalers if possible, to prevent patients taking long-acting bronchodilators without ICS. If no combination product is available for the desired combination, carefully explain to the patient that it is very important that they continue taking the ICS.

Advise patients to follow their action plan or get medical advice within 24 hours if they develop symptoms suggestive of a lower respiratory tract infection (e.g. such as fever and/or increased sputum production and/or increased shortness of breath).

Identify and manage comorbidities and other risk factors for flare-ups (e.g. heart disease).

Provide an action plan and update it regularly.

**Inhaled corticosteroid treatment (essential)**

Treatment is based on regular ICS at low-to-moderate doses (see *Australian Asthma Handbook* for definition of doses). ICS treatment is essential to reduce the risk of potentially life-threatening asthma flare-ups, even if asthma symptoms appear mild. In a well-conducted case-control study, patients with COPD who had a history of asthma had a significantly lower risk of hospitalisation or death if they were started on treatment with ICS/LABA combination therapy than with LABA alone.

**Long-acting bronchodilators**

The addition of a LAMA or LABA (Table 3) to ICS is needed in most cases. Some patients may benefit from the combination of all three classes.

LABAs and LAMAs should not be used by people with asthma or asthma–COPD overlap unless they are also taking an ICS (either in combination or separately).

If possible, minimise the number of different types of inhaler devices to avoid confusion about inhaler technique. More information on inhaler technique is available from: National Asthma Council Australia, Lung Foundation Australia

**Other treatments**

Pulmonary rehabilitation is effective for people with symptomatic COPD. Supervised exercise training may help improve asthma symptoms and quality of life in people with asthma–COPD overlap, including older people.

Comorbid medical conditions are common among people with coexisting asthma and COPD. Comorbidities should be assessed and managed individually.
Table 3. Long-acting bronchodilators for asthma–COPD overlap

<table>
<thead>
<tr>
<th>Class</th>
<th>Dosing frequency</th>
<th>Agent</th>
<th>Brand name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Fluticasone furoate + vilanterol</td>
<td>Breo Ellipta &quot;</td>
</tr>
<tr>
<td>ICS–LABA combinations</td>
<td>Once daily</td>
<td>Budesonide + formoterol</td>
<td>Symbicort Rapihaler</td>
</tr>
<tr>
<td></td>
<td>Twice daily</td>
<td>Fluticasone propionate + formoterol</td>
<td>Symbicort Turbuhaler</td>
</tr>
<tr>
<td></td>
<td>Twice daily</td>
<td>Fluticasone propionate + salmeterol</td>
<td>Fluticasone and Salmeterol Cipla</td>
</tr>
<tr>
<td></td>
<td>Twice daily</td>
<td>Indacaterol</td>
<td>Onbrez Breezhaler</td>
</tr>
<tr>
<td>LABAs *</td>
<td>Once daily</td>
<td>Formoterol</td>
<td>Oxis</td>
</tr>
<tr>
<td></td>
<td>Twice daily</td>
<td>Salmeterol</td>
<td>Serevent Accuhaler</td>
</tr>
<tr>
<td>LAMAs *</td>
<td>Once daily</td>
<td>Glycopyrronium</td>
<td>Seebri Breezhaler</td>
</tr>
<tr>
<td></td>
<td>Once daily</td>
<td>Tiotropium</td>
<td>Spiriva</td>
</tr>
<tr>
<td></td>
<td>Once daily</td>
<td>Umclidinium</td>
<td>Spiriva Respimat</td>
</tr>
<tr>
<td></td>
<td>Twice daily</td>
<td>Acclidinium</td>
<td>Incruse Ellipta</td>
</tr>
<tr>
<td></td>
<td>Twice daily</td>
<td>Indacaterol + glycopyrronium</td>
<td>Ultibro Ellipta</td>
</tr>
<tr>
<td>LABA–LAMA combinations</td>
<td>Once daily</td>
<td>Olodaterol + tiotropium</td>
<td>Spiolto Respimat</td>
</tr>
<tr>
<td></td>
<td>Once daily</td>
<td>Vilanterol + umclidinium</td>
<td>Anoro Ellipta</td>
</tr>
<tr>
<td></td>
<td>Twice daily</td>
<td>Formoterol + aclidinium</td>
<td>Brimica Genuair</td>
</tr>
</tbody>
</table>

* Important! Ensure that patient is also using regular long-term ICS. LABAs and LAMAs should not be used by people with asthma or asthma–COPD overlap unless they are also taking an ICS, in combination or separately.

# Only the 100/25 mcg dose of fluticasone furoate/vilanterol is approved by the Therapeutic Goods Administration (TGA) for treatment of COPD. The higher dose (200/25 mcg) is not approved by the TGA for the treatment of COPD, so it should not be used in people with asthma–COPD overlap.

High doses of ICS (alone or in combination) are not recommended in patients with COPD and should therefore be used with caution in patients with asthma–COPD overlap, because of the risk of pneumonia.

Refer to PBS status before prescribing.

Holistic management

Management should also include smoking cessation, treatment of comorbid conditions, physical activity, pulmonary rehabilitation, vaccinations, self-management (including a regularly updated action plan) and regular follow-up. Action plan templates are available for asthma and for COPD. Choose an asthma action plan or COPD action plan depending on the patient’s dominant clinical features.

Respiratory tract infections should be monitored carefully because people with asthma–COPD overlap have high morbidity rates and because ICS treatment (particularly fluticasone propionate) is associated with increased risk of non-fatal pneumonia in people with COPD. Most of the available evidence is from patients treated with fluticasone propionate. Increased pneumonia rates have also been observed in studies of patients with COPD using fluticasone furoate/vilanterol. The higher dose of fluticasone furoate/vilanterol (Breo Ellipta 200/25 mcg) is not TGA-approved for patients with COPD, so it should not be used in patients with asthma–COPD overlap.

Specialist referral

Specialist referral should be considered for patients with atypical symptoms or symptoms that suggest an alternative diagnosis, persistent symptoms or flare-ups despite treatment, or complex comorbidities.
References


4. Gibson PG, Simpson JS. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728-735.

5. Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax 2015; 70: 683-691.


More information

For more information, including patient resources and support, health professional publications and training, and inhaler technique how-to videos, visit: nationalasthma.org.au lungfoundation.com.au

Treatment guidelines:

- Australian Asthma Handbook asthmanhandbook.org.au
- The COPD-X Plan: Australian and New Zealand guidelines for the management of COPD copdx.org.au
- COPD-X Concise Guide for Primary Care copdx.org.au

Evidence-based publications from National Asthma Council Australia:

- Stepwise Management of Stable COPD
- Primary Care Respiratory Toolkit
- COPD Action Plan

Acknowledgements

This information paper was prepared in consultation with the following health professionals:

- Professor Christine McDonald, respiratory physician
- Professor Helen Reddel, respiratory physician
- Dr Kerry Hancock, general practitioner
- Rhona MacDonald, nurse practitioner
- Associate Professor Bandana Saini, pharmacist

Funded by a grant from AstraZeneca Australia. Apart from providing a financial grant, AstraZeneca has not been involved in the development, recommendation, review or editing of this publication.

Recommended Citation


Disclaimer

Although all care has been taken, this information paper is a general guide only, which is not a substitute for assessment of appropriate courses of treatment on a case-by-case basis. The National Asthma Council Australia and Lung Foundation Australia expressly disclaim all responsibility (including for negligence) for any loss, damage or personal injury resulting from reliance on the information contained herein.